Skip to Content
Merck
All Photos(1)

Key Documents

SAB2501521

Sigma-Aldrich

Anti-PCSK9 antibody produced in goat

affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-FH3, Anti-HCHOLA3, Anti-LDLCQ1, Proprotein convertase subtilisin/kexin type 9

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

goat

Quality Level

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

mouse, human, rat

technique(s)

indirect ELISA: suitable
western blot: suitable

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... PCSK9(255738)

General description

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) codes for a secretory serine protease predominantly expressed in liver and intestine. The PCSK9 gene is mapped to human chromosome 1p32.3 and is highly polymorphic.. PCSK9 is also expressed in vascular smooth muscle cells.

Immunogen

Peptide with sequence TRFHRQASKCDSHGT, from the internal region of the protein sequence according to NP_777596.2

Biochem/physiol Actions

PCSK9 (proprotein convertase subtilisin/Kexin Type 9) promotes lysosomal degradation of LDLR (low density lipoprotein receptor), VLDL (very low density lipoprotein receptor) and LRP (LDL related protein) to cause clearance of plasma cholesterol. On the other hand, PCSK9 also stimulates the release of chylomicron in intestinal cells. Lower intracellular cholesterol and mutations such as gain of function stimulates the expression of PCSK9. Autosomal dominant hypercholesterolemia is a result of high LDLR-degradation caused due to mutated PCSK9. PCSK9 is known to prevent the entry and replication of hepatitis C virus. PCSK9 expression is observed in atherosclerotic plaques.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.
Arama C, et al.
PLoS ONE, 13(2), e0192850-e0192850 (2018)
Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
Ruscica M, et al.
Journal of the American Heart Association, 6(5), e005764-e005764 (2017)
Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity.
Li Z and Liu Q
Biochemical and Biophysical Research Communications, 496(4), 1229-1235 (2018)
What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.
Qiu C, et al.
Lipids in Health and Disease, 16(1), 111-111 (2017)
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese E P, et al.
European heart journal. Cardiovascular pharmacotherapy, 2(1), 44-53 (2015)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service